EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

17 Drugs in Development

17 Drugs in Development

DIGITAL CONTENT

19 NEWS #PharmaBuzz

media
19 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 Annual Reports

globalSalesInformation
3 Annual Reports

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

17DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Volitinib, 1313725-88-0, Azd-6094, Hmpl-504, Azd6094, Savolitinib [inn]

Molecular Formula

C₁₇H₁₅N₉

Molecular Weight

345.4 g/mol

InChI Key

XYDNMOZJKOGZLS-NSHDSACASA-N

FDA UNII

2A2DA6857R

Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.

1 2D Structure

Savolitinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine

2.1.2 InChI

InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1

2.1.3 InChI Key

XYDNMOZJKOGZLS-NSHDSACASA-N

2.1.4 Canonical SMILES

CC(C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C

2.1.5 Isomeric SMILES

C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C

2.2 Other Identifiers

2.2.1 UNII

2A2DA6857R

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)triazolo(4,5-b)pyrazine

2. Azd6094

3. Hmpl-504

4. Volitinib

2.3.2 Depositor-Supplied Synonyms

1. Volitinib

2. 1313725-88-0

3. Azd-6094

4. Hmpl-504

5. Azd6094

6. Savolitinib [inn]

7. Hmpl504

8. (s)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-[1,2,3]triazolo[4,5-b]pyrazine

9. Chembl3334567

10. 2a2da6857r

11. 1h-1,2,3-triazolo(4,5-b)pyrazine, 1-((1s)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1h-pyrazol-4-yl)-

12. 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine

13. Orpathys

14. Unii-2a2da6857r

15. Azd6094, Hmpl-504

16. Volitinib(savolitinib)

17. Azd-6094volitinib

18. Savolitinib (usan/inn)

19. Savolitinib [usan:inn]

20. Savolitinib [usan]

21. Savolitinib [who-dd]

22. Gtpl9918

23. Hmpl 504

24. Schembl12489208

25. Ex-a845

26. Dtxsid801111016

27. Azd 6094

28. Bdbm50023342

29. Mfcd28359096

30. Nsc782121

31. Nsc800966

32. S7674

33. Akos030526403

34. Savolitinib(azd6094, Hmpl-504)

35. Zinc149738712

36. Ccg-267976

37. Db12048

38. Nsc-782121

39. Nsc-800966

40. Compound 28 [pmid: 25148209]

41. Ncgc00475727-01

42. Ac-35267

43. As-35250

44. Bv160378

45. Hy-15959

46. Savolitinib;volitinib;hmpl-504;azd-6094

47. A14419

48. D11139

49. J-690125

50. Q27254463

51. (3e)-5-chloro-3-[(5-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}-2-furyl)methylene]-1,3-dihydro-2h-indol-2-one Hydrochloride

52. 1-((s)-1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)-triazolo(4,5-b)pyrazine

53. 4-{1-[(1s)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1h-pyrazole

2.4 Create Date

2012-11-30

3 Chemical and Physical Properties

Molecular Formula	C₁₇H₁₅N₉
Molecular Weight	345.4 g/mol
XLogP3	1.5
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Exact Mass	345.14504152 g/mol
Monoisotopic Mass	345.14504152 g/mol
Topological Polar Surface Area	91.6 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	505
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of lung cancer

Treatment of renal neoplasms

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find API Reference Price of Savolitinib on PharmaCompass.com

Savolitinib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

17 Drugs in Development

DIGITAL CONTENT

19 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 Annual Reports

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

17DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?